Brain tumours have a high mortality rate and are the most common solid tumour of childhood. MRS is a non-invasive imaging technique that measures tumour metabolites which can provide prognostic information to aid clinical management. The metabolite glycine is associated with proliferation and tumorigenesis through the one-carbon metabolic cycle. Glycine concentration has been shown to increase with tumour grade using short echo time MRS at 1.5T, however has not been assessed as a survival marker. This study investigates glycine as a marker of survival in paediatric brain tumours and assesses its added value compared to other established metabolite survival markers.